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Methods: In the absence of long-term prospective studies from early adulthood specifically designed
to address this question, a group of international experts examined evidence presently available from
previous clinical and population studies to provide an evidence-based opinion as to whether such a
change in conceptualization may be justified.
Results: Although still lacking confirmation from dedicated prospective biomarker studies, there is
already considerable evidence to suggest both risk factor exposure and brain changes may be already
present in midlife.
Discussion: Current evidence suggests (1) that a change in clinical approach notably involving pro-
motion of cardiovascular health in persons with a family history of AD may considerably reduce dis-
ease risk and (2) that the development of biomarkers at this early stage will lead to the possibility of
clinical trials at a much earlier stage.
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Both clinical practice and research in sporadic Alz-
heimer’s disease (AD) have long been based on the dual as-
sumptions that it is a disorder of old age and synonymous
with dementia. Research has thus targeted elderly cohorts,
taking the onset of cognitive decline with accompanying
functional loss in everyday activities as the point of disease
onset. Clinical practice has followed from these conclusions
with AD being excluded as a diagnosis in the absence of
signs of dementia. Epidemiologic observations suggest,
however, that exposure to the principal risk factors occurs.
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commons.org/licenses/by-nc-nd/4.0/).much earlier [1,2] with simulation studies indicating that
very significant decreases in population incidence might
be obtained by targeting simultaneously multiple high-risk
factors occurring in midlife, notably cardiovascular risk fac-
tors, depression, poor diet, activity levels, and insulin resis-
tance. Such interventions appear to be potentially more
powerful than even modification of the principal genetic
risk factor [1]. This together with increasing evidence of
brain changes in genetically at-risk younger persons, and
theoretical models of biomarker progression indicating
most significant changes to occur years if not decades before
diagnosis [3,4], has led us to question current assumptions.
An alternative hypothesis is that sporadic AD is not a dis-
ease of the elderly but rather a clinically silent pathology of
midlife (approximately 40–65 years or even younger), whose
terminal phase is characterized by dementia. If this were so,imer’s Association. This is an open access article under the CC BY-NC-ND
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considered a disease of end-of-life but rather a disease of
the young. The clinical consequences of such a changewould
also be significant, reorientating disease management away
from palliative care to active prevention strategies in
younger, healthier individuals. Screening of high-risk
younger adults using innovative biomarkers and more sensi-
tive cognitive assessments may then be followed by midlife
intervention programs in parallel with the development of
new potential drug targets. Disease-modifying drugs which
have previously failed on clinical testing may further prove
more efficacious at earlier ages for secondary prevention.
In this context, there are a number of key questions which
may be asked.
Is there biomarker and clinical evidence to suggest AD
may be present in nonsymptomatic persons in the decades
before diagnosis?
Do longitudinal population studies which have tracked
normal persons frommidlife up to a diagnosis of AD confirm
clinical biomarker studies?
Can epidemiologic studies suggest which risk factors dur-
ing the preclinical period would be most strongly associated
with a later diagnosis of dementia due to AD?
If AD is reconceptualized as a disorder of midlife, what
are the consequences for clinical practice?2. Methods
International experts in the areas of epidemiology, brain
imaging, and clinical research were asked to consider
currently available evidence thatmight support the conceptu-
alization of AD as a disease of the young on the basis of cur-
rent research and clinical experience. The literature relating
to preclinical, biological, and clinical markers is vast, meth-
odologically heterogeneous, and difficult for a nonspecialist
to interpret. This overview does not attempt a comprehensive
review of all the literature but rather provides critical sum-
mary statements derived from expert reading of current evi-
dence illustrated by the most significant and robust findings
which would be more accessible to the nonspecialist. The
aim has thus not been to provide an exhaustive systematic re-
view but rather to open a debate using the currently available
empirical evidence to determinewhether it is time to reframe
our current conceptualization of this disorder.3. Results
3.1. Evidence for preclinical brain changes
A potentially useful way to approach the complex prob-
lem of midlife brain changes is to subdivide the question
into two separate parts: (1) when can subtle cognitive
changes relating to AD first be observed and (2) when do
subtle biological changes relating to AD start? We outline
certain recent but also older studies that have attempted to
address these issues.We briefly note that although the main focus of this article
is midlife changes, the exact earliest timing of either cogni-
tive or biological changes in relation to AD is not known;
there is research suggesting alterations even at young age
or even at childhood. To the degree that such early changes
are directly linked with AD and related dementia manifesta-
tions, they add considerable additional support to the argu-
ment of reorienting our scientific and research decades
before late-life. “When do subtle cognitive changes start?”
Findings from the Nun study have suggested that linguistic
ability obtained from autobiographies at the age of 22 (as
quantified in the form of idea density and grammatical
complexity) relate not only to cognitive function 58 years
later but also to AD–related neuropathologic measures
(neurofibrillary tangles) in late-life [5]. Moving the clock
even earlier, data from the 1946 Medical Research Council
birth cohort in England, Scotland and Wales suggest that
an overall mental ability test (including assessment of anal-
ogies, comprehension, numerical reasoning, matching,
spatial analysis, and nonverbal reasoning) as well a test of
verbal comprehension at age 15, were related to decline in
memory (word-list learning) and speed-concentration
(timed visual search) decline between the ages 43 and 53
[6]. An even earlier birth cohort from Britain suggested
similar associations. Subjects born in 1921 in the Lothian
birth cohort who were evaluated cognitively with the Moray
House test in 1932 (age 11) were followed for dementia
diagnosis up to 1997: late-onset dementia was associated
with lower mental ability scores in childhood [7]. Subse-
quent analyses from the same cohort suggested that lower
childhood cognitive scores were noted for vascular dementia
cases (rather than AD) [8].
“When do subtle biological changes relating to AD
start?” There have been a series of publications examining
APOE-related structural and functional brain changes
before late-life [9]. Middle-aged cognitively normal ε4 car-
riers have been shown to have cerebral metabolic reduc-
tions (as assessed by fludeoxyglucose positron emission
tomography) in areas where metabolic deficits are usually
noted in patients with Alzheimer’s dementia (i.e. parietal,
parietotemporal, posterior cingulate, frontal, and so forth)
[10]. A similar cerebral metabolic pattern has been demon-
strated also for young ε4 carriers [11]. APOE-related cere-
bral blood flow changes have been demonstrated even for
college age subjects [12]. Moving the clock even earlier,
structural brain imaging in 162 healthy typically devel-
oping 2–25 month-old infants suggested differences in
white matter myelin water fraction and gray matter volume
between ε4 carriers and noncarriers [13].
Moving from APOE (as a surrogate of AD–related
changes) to amyloid per se, probably the most central neuro-
pathologic change underlying AD, at least two studies have
examined rates of amyloid accumulation with repeated PET
brain imaging over time. According to data from 200 partic-
ipants received repeated 11C-PIB imaging every 1.5 years
over the course of 3.8 years as part of the Australian Imaging
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12 years to move from amyloid values noted in healthy con-
trols to an amyloid positivity threshold and an additional
19 years to reach amyloid levels noted in established Alz-
heimer’s dementia [14]. According to data from 246 partic-
ipants from the Mayo Clinic group who underwent repeated
amyloid imaging, it was estimated that the time required to
move from a low threshold of amyloid positivity (standard
uptake value ratio of 1.5) to that often noted in Alzheimer’s
Dementia (standard uptake value ratio levels of 2.5) is
approximately 15 years [15].
Other studies provide more direct AD–related neuropath-
ologic information in younger subjects. In a cohort of 2332
brains, neuropathologic information was available in slightly
more than 700 who were aged 60 years [16]. Pretangle
formations were noted at brainstem nuclei in the ages
10–30 years and in the cortical transentorhinal regions at
ages 30–50 years. Neurofibrillary tangles stages I–II were de-
tected in more than 25% in the 30s, close to 40% in the 40s,
and close to 50% in the 50s. Neurofibrillary tangles stages
III–IV started mostly in the 60s and 70s, while stages V–VI
even later. Amyloid pathology was seen mostly in older
adults, but some degree of amyloid deposition was seen in
w30% in the 60s. Another study investigated patterns and
types of amyloid-b accumulation, particularly of the fibrillo-
genic 42-amino acid isoform, in brains of 13 normal younger
(20–66 years) subjects in comparison with normal aged, AD
patients and elderly with very high memory performance
[17]. Amyloid-b1–42 immunoreactivity was observed intra-
neuronally in the entire cholinergic population in basal fore-
brain quite selectively, early in adult life and regardless of
age. Increases in the prevalence of intermediate and large
molecular weight soluble oligomer species were observed
in aged andAlzheimer brains when comparedwith the young.
Familial AD offers another excellent paradigm that can
provide insights into this question. According to brain amy-
loid imaging results from the Columbian presenilin 1 E280A
mutation cohort, fibrillar amyloid seems to begin to accumu-
late about 16 and 21 years before the predicted ages of mild
cognitive impairment (MCI) and dementia onset (i.e. 40–
60 years old) [18]. Analyses from the same cohort suggested
that MRI atrophy changes, hippocampal and parahippocam-
pal functional MRI activation changes, cerebro-spinal fluid
Ab42, and plasma Ab42 changes in mutation carriers can
be detected between the ages of 18 and 26 [19]. Along
similar lines, data from 128 subjects with familial AD muta-
tions participating in the Dominantly Inherited Alzheimer’s
Network (DIAN) study suggested changes in many biolog-
ical markers many years before estimated dementia onset:
CSF Ab42 25 years; brain PET 11C-PIB Ab deposition
15 years; CSF t, and MRI atrophy 15 years [20].
Before subscribing to the possibility of very early AD–
related neurobiological changes, there are many other poten-
tial explanations for some of the early cognitive changes find-
ings. A suboptimal cognitive performance, even at a very
young age, could provide a lower threshold for dementia diag-nosis in later life, even with relatively lower accumulation of
AD–related neuropathologic changes. This suboptimal per-
formance may also lead to less healthy or more “neurotoxic”
lifestyle choices, which may in turn lead to higher dementia
risk (as suggested for example by the association of childhood
abilities with higher vascular dementia incidence in late-life
[5]). Both early subtle cognitive underperformance and late-
life dementia could be also related via another underlying fac-
tor (i.e. a common genetic susceptibility).
Regarding early biological changes, very early APOE-
related brain imaging alterations (even in infancy) may
very well represent an APOE-related neurophysiological
heterogeneity rather than early AD–related biological pro-
cesses. This heterogeneity may in turn predispose to later
AD–related processes. Overall, beyond these caveats, it
emerges quite clearly from most studies that AD–related
pathologic changes (brain, CSF and plasma Ab, brain atro-
phy and CSF) start quite a few years before overt clinical
symptoms and deficits—most likely at middle age.
Summarizing, current state of knowledge does not permit
a solid and undisputable direct conclusion that such early
changes equal early Alzheimer’s neuropathologic changes.
Additionally, the magnitude of detectable changes (either
clinical or biological) in young age is often small. Therefore,
although it may carry predictive value, it may not be of clin-
ical significance at much younger ages.
We should also keep in mind that there are many limita-
tions in our current ability to estimate exactly when, what,
and how. There are well-known differences between familial
and sporadic AD. Imaging and CSF biomarker data for
healthy middle-aged persons are largely cross-sectional or
with very short follow-up. Similarly, imaging and CSF
biomarker data regarding mutation carriers are largely
cross-sectional with use of estimated rather than actual age
of onset, which may prove to be inaccurate with actual lon-
gitudinal data [21]. Finally, we are lacking important infor-
mation (either imaging or CSF, either cross-sectional or
longitudinal) on many other important underlying
dementia-related neurobiological processes (i.e. a-synu-
clein, TDP-43, and so forth). Some of these shortcomings
are being addressed by new cohort studies designed specif-
ically to look closely at brain changes, biomarkers, cogni-
tion, and risk factors in midlife.3.2. Evidence from long-term population studies
Long-term population studies have also provided consider-
able evidence to suggest that late-life Alzheimer’s dementia
may be linked to exposures occurring in early and midlife.
From the prospective population study of women in Gothen-
burg, which started in 1968 with last follow-up in 2010, it
has been reported that higher blood pressure [22], the person-
ality factor neuroticism [23], psychosocial stress [24], number
of stressful events [25], poorer lung function [26], oral health
[27], diabetes [28], obesity [28], low physical activity [28],
larger waist-hip ratio [29], and consumption of spirits [30]
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ring more than three decades later. In contrast, wine drinking
reduced the risk [30]. In addition, high levels of homocysteine
increased the risk for late-life mixed dementia [31]. Further-
more, trajectories of blood pressure [22], cholesterol [32],
and body mass index [33] differed over more than three de-
cades between those who developed dementia and those
who did not. In these studies, risk factor decline in late-life
was associated with increased dementia risk which may indi-
cate a difference in the role of risk factors between mid- and
late-life but could also be due to reverse causality [34]. In
the population study H70, it was found that the number of
stressful events during life was proportionally related to
increased risk for dementia between ages 70 and 79 years
[35], with the most significant events occurring before age
16 years. Depressive symptomatology associated with Alz-
heimer’s dementia has commonly been considered a reaction
to loss of competency; however, there is now evidence to sug-
gest that it is a highly significant midlife risk factor [1,2]
whose treatment may significantly reduce later Alzheimer’s
dementia risk [36].
Support for the notion that very early factors in life may
constitute important risk factors for late-life pathology is also
confirmed by the finding that smaller total intracranial volume
on computed tomography (CT) at age 85 years was related to
increased odds of dementia [37]; intracranial volume being an
indicator of brain size at age 5 years. Further support for the
idea that risk factors appear decades before onset of Alz-
heimer’s dementia is the observation that higher blood pressure
[38] and being overweight [39] at age 70 years were related to
increased risk of dementia after age 80 years. In addition,
several Alzheimer’s dementia risk factors have also been iden-
tified as risk factors for preclinical AD [40,41]. In considering
risk and protective factors for Alzheimer’s dementia, it is
necessary to take into account the observations described in
the preceding section indicating that early changes in CSF b-
amyloid may occur 2–3 decades before clinical onset of
Alzheimer’s dementia [4]. This means that the earliest patho-
logic events may already have occurred when the risk factors
are measured. It may therefore be more pertinent to talk about
promoters or delayers of the disease process. This may have
important implications for prevention in the future, as those
with low levels of CSF b-amyloid in midlife may derive
more benefit from preventive activities, such as diet, exercise,
brain stimulating activities, and treatment of vascular risk fac-
tors, than those with higher levels. However, it may also be so
that some of the designated “risk factors” for Alzheimer’s de-
mentia are actually early symptoms of the disease, even if
observed decades before clinical onset.
These observations should be seen in the light of findings
from the Honolulu Aging Study, where it was found that
higher midlife blood pressure was related to Alzheimer brain
pathology at autopsy in late-life [42], and the findings from a
neuropathologic study of brains from persons from middle to
old age which reported an association between hypertension
and Alzheimer pathology [43]. Ischemic white matter lesions(WMLs) on MRI [44] and CT [45] have also been related to
increased risk for dementia during follow-up. These late-life
changes have been associated with midlife diastolic hyper-
tension [46], giving a possible explanation for the association
between hypertension andAlzheimer’s dementia. Recently, it
was reported that therewas an association betweenWMLs on
MRI and lower levels of CSF b-amyloid already before
symptoms of dementia [47]. Similar associations have also
been observed for WMLs on CT (Skoog personal communi-
cation from analyses prepared for this discussion). This
might indicate an early association between b-amyloid and
vessel wall changes in the pathogenesis of AD, with previous
experimental evidence from Iadecola et al. [48] also suggest-
ing that vascular pathology may also in turn influence b-am-
yloid deposition. Similarly, several population-based studies,
including the Atherosclerosis Risk in Communities study,
the Framingham Offspring Cohort Study, and the Lothian
Birth Cohort, have found that physical activity and other
vascular risk factors such as cholesterol and diabetes are
associated with measures of atrophy and ischemia in older
adults [49–51]. Increasing evidence also suggests that an
increased burden of vascular risk factors contributes to the
accumulation of amyloid pathology [52].3.3. The central role of cardiovascular risk factors
Epidemiologic studies have established a critical role for
cardiovascular risk factors in the development of late-life
cognitive impairment and dementia; however, few studies
have considered the nature of this association in midlife or
before [34,49,53,54]. Emerging data from the Coronary
Artery Risk Development in Young Adults (CARDIA)
Study, a prospective cohort of young adults between the
ages of 18 and 30, indicate that cardiovascular risk factors
could affect cognitive health in earlier stages of the life-
course. Over a 25-year period, CARDIA repeatedly
measured cardiovascular risk factors and outcomes in over
3000 black and white participants, and at midlife (year 25
of the study, participant mean agez50) a cognitive evalua-
tion included three tests, the Rey auditory verbal learning
test, digit symbol substitution rest, and Stroop test. Prelimi-
nary results provide evidence for the contribution of cardio-
vascular risk factors across the life span.
In CARDIA, early adult cumulative exposure to cardiovas-
cular risk factors demonstrated significant associations with
midlife cognitive function [55]. Cumulative cardiovascular
risk factor exposure over 25 years was estimated by the area
under the curve for systolic blood pressure, diastolic blood
pressure, cholesterol, and fasting blood glucose. Cumulative
exposure to systolic and diastolic blood pressure as well as
fasting blood glucose was consistently associated with worse
performance on executive function, processing speed, and
verbal memory atmidlife, andwhen recommended guidelines
were used as cutoffs (defined as systolic blood pressure
.120 mm Hg, diastolic blood pressure .80 mm Hg, fasting
blood glucose .100 mg/dL, and total cholesterol .200 mg/
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cardiovascular risk factors and cognitive performance were
even stronger. For each standard deviation increase in cumu-
lative exposure to subclinical but elevated levels of cardiovas-
cular risk factors, standardized test scores were between 0.06
and 0.30 points less (P , .05, for all) adjusting for age, race,
sex, and education. Although effect sizes were small, these re-
sults highlight the critical role of cardiovascular risk factors
even beginning in young adulthood.
CARDIA findings also indicate that maintaining optimal
cardiovascular health contributes to better cognitive function
in midlife [57]. The American Heart Association has desig-
nated seven ideal cardiovascular health components which
include body mass index ,25 kg/m2, nonsmoking or quit-
ting.1-year ago, physical activity.150 minutes of moder-
ate activity or .75 minutes of vigorous activity/week, 4–5
components of a healthy diet, total cholesterol ,200 mg/
dL, blood pressure ,120/80 mm Hg, and fasting blood
glucose ,100 mg/dL [47]. Adults with a greater number
of ideal cardiovascular health components at both early
adulthood and midlife had better midlife cognitive perfor-
mance on all three cognitive tests. Furthermore, adults
who maintained ideal cardiovascular health over 25 years
had better executive function, processing speed, and verbal
memory at midlife (P for trend ,.01, for all).
Although poor cognitive performance is not AD, it re-
mains one of the most significant risk factors, being also
likely to reflect a diminution of cognitive reserve and capac-
ity to compensate for accumulating pathology. The evidence
presented here, along with complementary findings for addi-
tional components of cardiovascular risk, including subclin-
ical atherosclerosis and cardiorespiratory fitness [58] and
hypercholesterolemia [59,60] suggest that the pathologic
changes underlying poor cognitive performance are similar
to those associated with dementia as early as midlife. In
addition, although future studies will need to model
trajectories of cognitive function; these results warrant
consideration of prevention strategies that encompass
earlier stages of the life span.4. Discussion
4.1. What do we need to know?
Overall, this is an exciting but at the same time evolving
story and the overall picture is still quite incomplete. The
validation of the midlife hypothesis will require very long-
term follow-up of biomarker and subtle preclinical changes
in young adults and ideally birth cohorts. In the meantime,
further information is being obtained from epidemiologic
studies with longitudinal biological samples and validated
information on midlife risk exposures and clinical studies
of persons at high risk, such as the children of persons
with AD. Recently initiated prospective cohort studies in
mid-life such as the PREVENT Project [61] will yield
important information on the interplay between risk factorsand both biological and clinical features but also the
sequencing of disease processes. These data will then pro-
vide improved stratification of risk, better upstream targets
for secondary prevention, and clarity on optimal outcomes
to be used to measure an intervention’s effect in midlife.
Literature on very early biological and clinical changes
suggests that much more needs to be learned on biomarker
and clinical-cognitive alterations in younger ages. At pre-
sent, not much relevant scientific research has been conduct-
ed, but it would be very important to accumulate much more
information regarding proportions of amyloid and other
related biomarker positivity (either with PETor CSF studies)
in young subjects, alterations of more sensitive MRI struc-
tural changes, rates and directionality of biomarker and
structural changes at young age, the role and interaction of
APOE, and subtle cognitive performance indices with
respect to such biomarker changes and so forth.4.2. What will this mean for future treatment?
Although at present there is no empirical data which
would allow us to determine which markers in midlife are
most closely associated with an early disease process, and
even less the values which would permit individual diag-
nosis, there is sufficient evidence to suggest preventive mea-
sures in midlife are worthwhile. This underpins the global
effort to establish a platform (or series of platforms) on
which trials can take place which aim to prevent dementia
in people at very high risk of disease progression who
already have existing evidence of disease (as accurately in-
dexed by biomarkers) without a diagnosis of dementia.
One such initiative is the EPAD (European prevention of
Alzheimer’s dementia) project to be initiated in early
2015. This project will see the establishment of a large
cohort across Europe (n 5 6000) drawn from existing co-
horts. This cohort will provide data for better disease models
as well as feeding people into an adaptive, standing proof of
concept trial (n 5 1500) with multiple arms that will accel-
erate drug development (and potentially nonpharmacologic
interventions) toward secondary prevention. Provided
efforts such as EPAD (or other similar ones) are successful,
and similar research endeavors (possibly more biomarker
focused) could be extended to even younger ages.4.3. What does this mean for the clinician?
Until further information is available from biomarker
studies recently initiated in this area, what evidence does
exist suggests compellingly that from the point of view of
the clinician nomore than good practice in relation to cardio-
vascular risk, in particular for personswith a family history of
AD, is highly likely to be of benefit, if not in disease modifi-
cation, at least in pushing back the time to functional loss.
Following the example of the FINGER trial which has shown
beneficial effects on cognition in older high-risk persons
[62], a similar study is needed in younger at-risk persons
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sures. In this context, the use of dementia risk scores such
as cardiovascular risk factors aging and dementia as used in
the FINGER study may be of use in better designating
high-risk persons than simply family history. Alerting per-
sons inmidlifewith a family history to the importance of pos-
itive action andmonitoring not only cardiovascular health but
also rapid treatment of depression and insulin resistance is
likely to be effective in reducing dementia risk.More specific
modifications to lifestyle will be developed in the next few
years as dementia prevention becomesmore feasible, reason-
able, and backed within governmental and public heath cir-
cles. Epidemiologic research currently suggests that such
interventions will principally target cognitive and physical
activity, diet, and stressmanagement. Hormonal replacement
therapy is also being re-evaluated in the light of a consistently
demonstrated protective effect, but perhaps suitable only for
a subgroup of women who may in the future be genetically
determined [63]. Future nonpharmacologic intervention
guidelines for persons at high risk will thus cover the entire
life-course as presented in Fig. 1.
The next 10 years will witness an interesting shift in the
focus for both research and clinical care. Currently, on the dis-
ease course, focus has been on the population with MCI—
research money has flowed into understanding more about
the proximal markers of risk to developing dementia over
approximately a 5-year course. This has led to diagnostic pro-
posals from both the United States and Europe for “prodromal
AD” and “MCI due to AD” which—by adding biomarkers
to criteria—have implied a diagnostic entity for people who
have AD (as evidenced by an abnormal biomarker) but do not
satisfy criteria for a dementia using International Classification
of Diseases, Tenth Revision or Diagnostic and Statistical
Manual of Mental Disorders criteria. These diagnostic pro-
posals require further validation of the proposed biomarkersadolescence young adult adult
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Fig. 1. Theoretical timing of potential intervention windows for prevention/delay
impairment.with evidence to date suggesting much greater sensitivity
than specificity implying correct terminology would be MCI
“not” due to AD [64,65]. Clinical pathways have adjusted
accordingly with little net benefit to incidence or clinical
outcomes. This approach though has to be broadly welcomed.
Empirical data from large, prospective, deeply phenotyped
cohort studies will add much to the validation or indeed the
adaptation of these criteria as more accurate disease models
are developed. Such criteria then form the basis of patient
stratification for specific secondary prevention approaches. In
effect, advances in understanding of the disease processes
leading to dementia and the associated massive burdens being
placed on individuals and society will mediate this focus
dissipating in two directions—earlier and later—so that
research will take place at a point earlier in the disease course
and target primary and secondary prevention in midlife and
later in the disease course to improve palliative care we can
provide through both psychosocial and pharmacologic
interventions for people with a dementia syndrome now
recognized as due to the brain failure associated with multiple
pathologic processes and not specific to for instance just AD.
Ultimately success in prevention will reduce the need for
services and research in dementia. This will obviously not be
easy but recent initiatives such as EPAD highlight an
incredible willingness by governments, academics, the public,
and commercial sectors to change the way we conceptualize
AD and the care paradigm. This conceptualization must
allow us to draw a distinction between AD (a specific
pathologic process), which may originate and develop from
midlife with Alzheimer’s dementia, which is the clinical
consequence of AD once dementia is established which also
involves other neurodegenerative disease processes that may
be dependent on or independent of AD, such as
cerebrovascular disease, oxidative stress, mitochondrial
dysfunction, or neuroinflammation. Such a distinction willMCI
AD threshold
AD
ormonal Replacement Therapy
Palliative care
 and metabolic risk factors
logical factors (depression, stress)
ing of AD. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive
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outcomes fromboth epidemiologic and interventional research.
The views expressed in this article are those of the
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authors have no conflicts of interest to declare.CONCLUSION
 There is evidence from clinical studies of biomarker
changes at midlife in persons at risk of future Alz-
heimer’s disease dementia; however, these studies
are cross-sectional.
 Prospective epidemiologic studies provide evidence
of a causal relationship between biomarker change
in midlife and later Alzheimer’s disease dementia.
 Epidemiologic studies indicate that the principal ex-
posures in midlife increasing risk for subsequent
Alzheimer’s disease dementia are cardiovascular,
metabolic, stress, and lifestyle factors.
 There is evidence to suggest that Alzheimer’s disease
may be present at midlife and that clinical interven-
tion at this stage based on known risk factors may
reduce the risk or slow progression to dementia.
 Secondary prevention trials that target individuals
with evidence of Alzheimer’s disease but without
dementia require both clinical and biological out-
comes reflective of progression of this disease rather
than reduction of incident Alzheimer’s disease de-
mentia which is a too distant outcome.RESEARCH IN CONTEXT
1. Systematic Review: Recent research suggests that
AD may begin decades before dementia is observed.
This research is reviewed by experts in biomarker
and epidemiological research.
2. Interpretation: While awaiting the results of on-going
research into biomarkers which may indicate new
treatments, clinical practitioners may be able to push
back the age of onset of dementia in persons at risk
(those with a family history) by monitoring and early
treatment of risk factors such as depression, diabetes
in its earliest possible stages for example by moni-
toring insulin resistance, low physical and cognitive
activity levels, and cardiovascular risk factors.
3. Future directions: Further evidence from birth co-
horts and midlife clinical intervention trials are
required to validate the hypothesis that Alzheimer’s
disease is present at midlife.References
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